drugset / Trial / NCT07354100

Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy

NCT07354100

Phase 1/2 Recruiting 55 enrolled University of Chicago
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to see if lactulose can improve the effectiveness of immunotherapy in patients with advanced cancer.

Timeline

Start
2026-12-15
Primary completion
2029-04-13
Completion
2029-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactulose Other / unclassified 10 mg
Subject Lactulose Other / unclassified 10 g

Indications